Patents by Inventor Sean O'Herrin

Sean O'Herrin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120141482
    Abstract: Extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules to provide soluble multivalent molecular complexes with high affinity for their cognate ligands. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection.
    Type: Application
    Filed: February 9, 2012
    Publication date: June 7, 2012
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jonathan Schneck, Sean O'Herrin, Michael S. Lebowitz, Abdel Hamad
  • Publication number: 20110243967
    Abstract: Extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules to provide soluble multivalent molecular complexes with high affinity for their cognate ligands. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection.
    Type: Application
    Filed: June 9, 2011
    Publication date: October 6, 2011
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jonathan Schneck, Sean O'Herrin, Michael S. Lebowitz, Abdel Hamad
  • Patent number: 7973137
    Abstract: Compositions comprising a cell in which a molecular complex with high affinity for its cognate ligand is bound to the surface of the cell are provided. To form the molecular complexes, extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection. Optionally, identical antigenic peptides can be bound to each ligand binding site of a molecular complex.
    Type: Grant
    Filed: August 22, 2000
    Date of Patent: July 5, 2011
    Assignee: Johns Hopkins University
    Inventors: Jonathan Schneck, Sean O'Herrin, Michael S. Lebowitz, Abdel Hamad
  • Publication number: 20040204565
    Abstract: To increase the effective affinity of soluble analogs of peptide/MHC molecules for their cognate ligands, divalent peptide/MHC complexes were constructed. Using a recombinant DNA strategy, DNA encoding the MHC class I was ligated to DNA coding for murine Ig heavy chain. MHC/Ig complexes were exploited to homogeneously load with peptides of interest. The results of flow cytometry demonstrated that the pepMHC/Ig complexes bound specifically with high affinity to cells bearing their cognate receptors.
    Type: Application
    Filed: April 5, 2004
    Publication date: October 14, 2004
    Applicant: The Johns Hopkins University
    Inventors: Jonathan Schneck, Drew Pardoll, Sean O'Herrin, Jill Slansky, Tim Greten
  • Patent number: 6734013
    Abstract: To increase the effective affinity of soluble analogs of peptide/MHC molecules for their cognate ligands, divalent peptide/MHC complexes were constructed. Using a recombinant DNA strategy, DNA encoding the MHC class I was ligated to DNA coding for murine Ig heavy chain. MHC/Ig complexes were exploited to homogeneously load with peptides of interest. The results of flow cytometry demonstrated that the pepMHC/Ig complexes bound specifically with high affinity to cells bearing their cognate receptors. pepMHC/Ig complexes are also useful in modulating effector functions of antigen-specific T cells. These pepMHC/Ig complexes are useful for studying TCR/MHC interactions and lymphocyte tracking and have uses as specific regulators of immune responses.
    Type: Grant
    Filed: February 22, 2001
    Date of Patent: May 11, 2004
    Assignee: The Johns Hopkins University
    Inventors: Jonathan Schneck, Drew Pardoll, Sean O'Herrin, Jill Slansky, Tim Greten
  • Patent number: 6458354
    Abstract: Extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules to provide soluble multivalent molecular complexes with high affinity for their cognate ligands. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection.
    Type: Grant
    Filed: September 25, 2000
    Date of Patent: October 1, 2002
    Assignee: The Johns Hopkins University
    Inventors: Jonathan Schneck, Sean O'Herrin, Michael S. Lebowitz, Abdel Hamad
  • Publication number: 20020127231
    Abstract: Specificity in immune responses is in part controlled by the selective interaction of T cell receptors with their cognate ligands, peptide/MHC molecules. The discriminating nature of this interaction makes these molecules, in soluble form, good candidates for selectively regulating immune responses. Attempts to exploit soluble analogs of these proteins has been hampered by the intrinsic low avidity of these molecules for their ligands. To increase the avidity of soluble analogs for their cognates to biologically relevant levels, divalent peptide/MHC complexes or T cell receptors (superdimers) were constructed. Using a recombinant DNA strategy, DNA encoding either the MHC class II/peptide or TCR heterodimers was ligated to DNA coding for murine Ig heavy and light chains. These constructs were subsequently expressed in a baculovirus expression system.
    Type: Application
    Filed: September 18, 2001
    Publication date: September 12, 2002
    Inventors: Jonathan Schneck, Sean O'Herrin
  • Patent number: 6448071
    Abstract: Specificity in immune responses is in part controlled by the selective interaction of T cell receptors with their cognate ligands, peptide/MHC molecules. The discriminating nature of this interaction makes these molecules, in soluble form, good candidates for selectively regulating immune responses. Attempts to exploit soluble analogs of these proteins has been hampered by the intrinsic low avidity of these molecules for their ligands. To increase the avidity of soluble analogs for their cognates to biologically relevant levels, divalent peptide/MHC complexes or T cell receptors (superdimers) were constructed. Using a recombinant DNA strategy, DNA encoding either the MHC class II/peptide or TCR heterodimers was ligated to DNA coding for murine Ig heavy and light chains. These constructs were subsequently expressed in a baculovirus expression system.
    Type: Grant
    Filed: June 3, 1999
    Date of Patent: September 10, 2002
    Assignee: The Johns Hopkins University
    Inventors: Jonathan Schneck, Sean O'Herrin
  • Publication number: 20020006903
    Abstract: To increase the effective affinity of soluble analogs of peptide/MHC molecules for their cognate ligands, divalent peptide/MHC complexes were constructed. Using a recombinant DNA strategy, DNA encoding the MHC class I was ligated to DNA coding for murine Ig heavy chain. MHC/Ig complexes were exploited to homogeneously load with peptides of interest. The results of flow cytometry demonstrated that the pepMHC/Ig complexes bound specifically with high affinity to cells bearing their cognate receptors.
    Type: Application
    Filed: February 22, 2001
    Publication date: January 17, 2002
    Inventors: Jonathan Schneck, Drew Pardoll, Sean O'Herrin, Jill Slansky, Tim Greten
  • Patent number: 6268411
    Abstract: To increase the effective affinity of soluble analogs of peptide/MHC molecules for their cognate ligands, divalent peptide/MHC complexes were constructed. Using a recombinant DNA strategy, DNA encoding the MHC class I was ligated to DNA coding for murine Ig heavy chain. MHC/Ig complexes were exploited to homogeneously load with peptides of interest. The results of flow cytometry demonstrated that the pepMHC/Ig complexes bound specifically with high affinity to cells bearing their cognate receptors. pepMHC/Ig complexes are also useful in modulating effector functions of antigen-specific T cells. These pepMHC/Ig complexes are useful for studying TCR/MHC interactions and lymphocyte tracking and have uses as specific regulators of immune responses.
    Type: Grant
    Filed: September 10, 1998
    Date of Patent: July 31, 2001
    Assignee: The Johns Hopkins University
    Inventors: Jonathan Schneck, Drew Pardoll, Sean O'Herrin, Jill Slansky, Tim Greten
  • Patent number: 6140113
    Abstract: Polynucleotides encode soluble, multivalent molecular complexes which modify immune responses, and host cells comprise such polynucleotides. The molecular complexes comprise extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, which are covalently linked to the heavy and light chains of immunoglobulin molecules to provide soluble multivalent molecular complexes with high affinity for their cognate ligands. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection.
    Type: Grant
    Filed: April 21, 1998
    Date of Patent: October 31, 2000
    Assignee: The Johns Hopkins University
    Inventors: Jonathan Schneck, Sean O'Herrin, Michael S. Lebowitz, Abdel Hamad
  • Patent number: 6015884
    Abstract: Specificity in immune responses is in part controlled by the selective interaction of T cell receptors with their cognate ligands, peptide/MHC molecules. The discriminating nature of this interaction makes these molecules, in soluble form, good candidates for selectively regulating immune responses. Attempts to exploit soluble analogs of these proteins has been hampered by the intrinsic low avidity of these molecules for their ligands. To increase the avidity of soluble analogs for their cognates to biologically relevant levels, divalent peptide/MHC complexes or T cell receptors (superdimers) were constructed. Using a recombinant DNA strategy, DNA encoding either the MHC class II/peptide or TCR heterodimers was ligated to DNA coding for murine Ig heavy and light chains. These constructs were subsequently expressed in a baculovirus expression system.
    Type: Grant
    Filed: March 28, 1997
    Date of Patent: January 18, 2000
    Assignee: The Johns Hopkins University
    Inventors: Jonathan Schneck, Sean O'Herrin